支气管扩张剂市场规模 - 按药物类别、给药途径、应用、配销通路、最终用途 - 全球预测

由于全球气喘、慢性阻塞性肺病 (COPD) 和支气管炎等呼吸系统疾病盛行率不断上升，支气管扩张剂市场规模在 2024 年至 2032 年间复合年增长率将达到 4.9%。根据世界卫生组织的数据，估计约有 3.92 亿人患有慢性阻塞性肺病。由于空气污染、吸烟和人口老化等因素，这些情况持续升级，对能够缓解症状和改善患者生活品质的有效药物的需求不断增长。

吸入装置和製剂的技术进步正在扩大支气管扩张剂治疗的可近性和有效性。干粉吸入器 (DPI)、定量吸入器 (MDI) 和雾化器的创新为患者提供了更方便、更精确的支气管扩张药物输送方法。正在进行的研发工作重点是开发安全性更高、效果更持久的新型支气管扩张剂疗法，将进一步推动市场成长。

整个产业分为药品类别、给药途径、应用、配销通路、最终用途和地区。

根据药物类别，黄嘌呤细分市场的支气管扩张剂市场规模预计到 2032 年将录得强劲增长，因为其在治疗哮喘和慢性阻塞性肺病等慢性呼吸道疾病方面的功效已被证实。黄嘌呤衍生物，如茶碱，透过放鬆气道平滑肌来改善气流并减轻症状，如喘息和呼吸短促。这些药物也用作维持治疗，以控制患者症状并防止病情恶化。

由于气喘应用领域的支气管扩张剂在全球范围内的盛行率不断增加，预计 2024 年至 2032 年期间将出现大幅复合年增长率。支气管扩张剂透过放鬆气道周围的肌肉来改善气流并缓解急性呼吸困难，从而帮助控制气喘症状。随着医疗保健系统专注于改善气喘管理和减少住院治疗，对针对气喘治疗的有效支气管扩张药物的需求将继续上升。

亚太地区支气管扩张剂产业将在 2024 年至 2032 年间实现强劲成长。这推动了对有效治疗方案的需求。各国政府也致力于透过宣传活动和医疗改革来改善呼吸道疾病管理，进一步促进区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 气喘和慢性阻塞性肺病等呼吸系统疾病的盛行率不断增加
    • 持续的研发工作和新产品批准
    • 支气管扩张剂的标籤外使用
  • 产业陷阱与挑战
    • 严格的监管框架
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药品类别，2021 - 2032 年

• 主要趋势
• β-肾上腺素能支气管扩张剂
• 抗胆碱能支气管扩张剂
• 黄嘌呤衍生物
• 其他药物类别

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 口服
• 可注射
• 吸入
• 其他给药途径

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 气喘
• 慢性阻塞性肺病（COPD）
• 其他应用

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AstraZeneca
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• Innoviva
• Medline Plus
• Merck & Co.,
• Mylan N.V.
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd

Bronchodilators market size will register a 4.9% CAGR between 2024 and 2032 driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis globally. As per WHO, approximately 392 million people are estimated to be living with COPD. With these conditions continuing to escalate due to factors like air pollution, smoking, and aging populations, there is growing demand for effective medications that can alleviate symptoms and improve the quality of life for patients.

Technological advancements in inhalation devices and formulations are expanding the accessibility and efficacy of bronchodilator treatments. Innovations in dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers are offering patients more convenient and precise delivery methods for bronchodilator medications. The ongoing R&D efforts focused on developing novel bronchodilator therapies with improved safety profiles and longer-lasting effects will further drive the market growth.

The overall industry is classified into drug-class, route of administration, application, distribution channel, end-use, and region.

Based on drug class, the bronchodilators market size from the xanthine segment is slated to record a strong growth rate through 2032 due to its established efficacy in managing chronic respiratory conditions like asthma and COPD. Xanthine derivatives, such as theophylline, work by relaxing the smooth muscles in airways to improve airflow and reducing symptoms, such as wheezing and shortness of breath. These medications are also used as maintenance therapy to control symptoms and prevent exacerbations in patients.

Bronchodilators market from the asthma application segment is projected to observe a substantial CAGR during 2024-2032 owing to its increasing prevalence worldwide. Bronchodilators help in managing asthma symptoms by relaxing the muscles around the airways to improve airflow and alleviate acute breathing difficulties. As healthcare systems focus on improving asthma management and reducing hospitalizations, the demand for effective bronchodilator medications tailored to asthma treatment will continue to rise.

Asia Pacific bronchodilators industry will witness a robust growth rate between 2024 and 2032. Rapid urbanization and industrialization in countries like China and India are making way for higher levels of air pollution, leading to greater incidence of respiratory conditions. This is driving the need for effective treatment options. Governments are also focusing on improving respiratory disease management through awareness campaigns and healthcare reforms, further boosting the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory disorders such as asthma and COPD
    • 3.2.1.2 Ongoing R&D efforts and new product approvals
    • 3.2.1.3 Off-label use of bronchodilators
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug-class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Beta-adrenergic bronchodilators
• 5.3 Anticholinergic bronchodilators
• 5.4 Xanthine derivatives
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Inhaled
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Asthma
• 7.3 Chronic obstructive pulmonary disease (COPD)
• 7.4 Other application

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Specialty clinics
• 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AstraZeneca
• 11.2 Boehringer Ingelheim International GmbH
• 11.3 Cipla Inc.
• 11.4 GlaxoSmithKline plc
• 11.5 Glenmark Pharmaceuticals Limited
• 11.6 Innoviva
• 11.7 Medline Plus
• 11.8 Merck & Co.,
• 11.9 Mylan N.V.
• 11.10 Novartis AG
• 11.11 Sun Pharmaceutical Industries Ltd
• 11.12 Teva Pharmaceutical Industries Ltd